The Edit Tirzepatide Review: $349/Month, the $300 Promo & Verdict (2026)

Compounded tirzepatide at The Edit is $349 a month if you pay month to month. The number the site puts in front of you first is $300, and that is a first-order promotion — one month, then $349 for every month after it. We read the company's own product catalog and its product pages in August 2026 and re-read every GLP-1 figure on 1 September 2026, when both standing rates had moved and the prepay rungs had not. Every figure below comes from the company's own published pages.

The tirzepatide ladder

There are three ways to buy it, and all three are published in the same place:

Now the part that is genuinely unusual: the arithmetic is honest. $855 divided by three is exactly $285. $1,575 divided by six is $262.50, which is where the advertised $263 comes from. Both prepay rungs are labeled "billed once at the start of the plan," so the commitment is stated rather than hidden inside a per-month figure. On this site we spend most of our time unpicking providers whose "/month" number is an annual prepay divided by twelve. The Edit is not doing that.

What it is doing is leading with the promotion, and printing it in larger type than the standing rate it is struck against. $300 is a real price you can pay — once. The word beside it is "LIMITED TIME", with no end date, no code and no statement of whether it reaches the prepay plans. If you are comparing providers on a spreadsheet, the cell that belongs in it is $349, and the cell that belongs beside it is $285 or $263 with the words "pay $855" or "pay $1,575 today" attached.

Who actually writes the prescription

The Edit Health LLC is a Texas MSO in Austin — the business layer. The clinical layer is Arora Health & Aesthetics, LLC, medical director Dr. Sean Arora, NPI 1841729449. We checked that number against the national provider registry: active, Seattle WA, family medicine, licensed in New Hampshire, Michigan and Washington.³ Naming a medical director and publishing an NPI that resolves is more than most of this category manages.

One thing to know before you treat this as a second opinion. Trellis Vitality, which sells tirzepatide at $199 a month, runs on the same medical group and the same medical director. Different pharmacies, different prices, genuinely separable products — but if you shortlist both and think you are choosing between two independent clinical organizations, you are not. You are choosing between two price sheets attached to one prescriber network.

The pharmacy is named, which is rarer than it should be

The Edit names The Pharmacy Hub as the compounder inside what it calls its pharmacy network. That is a checkable fact rather than the "an FDA-registered U.S. pharmacy" boilerplate that tells a reader nothing. Two of the providers we looked at in the same batch — Rehydra+ Wellness and Auren Rx — each name one pharmacy and state no 503A or 503B class for it.

Fees, refunds and getting out

Nothing is charged to start. The site's language is explicit: there is no charge and no card on file to begin, and if a clinician does not approve you, you are refunded in full. A visit fee becomes non-refundable once a visit has actually happened, which is a different and much fairer thing than a fee levied before anyone has looked at you.

Once the medication ships it is final sale, as compounded prescriptions generally are. Membership cancels at the end of the current period with no proration, under a cancellation policy the company dates to July 2026. The prepay plans are the place to be careful: a six-month plan is $1,575 you have already spent, and "cancel anytime" is about the subscription, not about that money.

The rest of the shelf

Compounded semaglutide is $259/month and compounded tirzepatide $349, with NAD+ at $249, glutathione at $199, sermorelin at $169 and GHK-Cu cream at $129 — the four peptide figures unchanged since August, while both GLP-1 rates rose.¹ The product list and the individual product pages agree with each other exactly, which sounds like a low bar until you have read enough of these sites to know how often two surfaces on the same domain publish two different prices.

There is no oral GLP-1, no nasal line, no retatrutide, and the site states plainly that it does not sell research-use-only compounds. Compare that with Pepti, whose catalog carries forty prescription peptide products alongside the tirzepatide.

The Spanish site

The Edit ships a complete `/es/` mirror — every page, thirty-three Spanish URLs in its own sitemap. No other row here does this. If English is not the language you want to read a consent form and a titration schedule in, that is a material difference and not a marketing flourish.

The regulatory screen

We ran the trading name, the legal entity, the medical group and the named pharmacy against the FDA's live warning-letter index in August 2026. Every query returned zero matches in the company column.² That screen carried a positive control — an unrelated telehealth seller with a real letter dated February 2026 — and the control returned correctly on every pass,⁴ so the zeroes here are evidence rather than a query that quietly failed. The Edit does not appear on either of the 2025 or 2026 compounded-GLP-1 sweeps.

Brand versus compounded

This is compounded tirzepatide, not Zepbound. Compounded tirzepatide is pharmacy-made, is not itself an FDA-approved finished drug, and was not the product studied in the pivotal trials. Our guide to whether compounded tirzepatide is still legal in 2026 sets out where that stands after the shortage ended.

Does the molecule work? (Separate question)

Keep the provider and the drug apart in your head. In the 72-week SURMOUNT-1 trial, adults without diabetes lost roughly 15% to 21% of body weight across the 5–15 mg doses, against about 3% on placebo⁵. Against semaglutide in SURMOUNT-5, tirzepatide produced about 20% versus 14%⁶. Both results came from the brand molecule at approved doses. The full picture is in our tirzepatide evidence guide.

The honest verdict

$349 a month is not cheap for compounded tirzepatide — it sits in the upper half of the field, and there are providers in our ranking charging a hundred dollars less for the same molecule. What The Edit buys you at that price is a set of things this category usually withholds: a named compounder, a named medical director with an NPI that resolves, a price ladder whose divisions are correct and whose commitments are labeled, no charge before a clinician has looked at you, and a full Spanish site. The one thing to hold onto is that $300 is a promotion and $349 is the price, and the second thing is that Trellis is not a second opinion on The Edit. Read the ladder against the rest of the field in our tirzepatide price index, or start from the ranked best tirzepatide providers ranking.